Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk.
PubWeight™: 1.05‹?›
| Rank: Top 15%
Published in Hum Mol Genet on August 28, 2014
Authors
Wei-Yu Lin1, Nicola J Camp2, Maya Ghoussaini3, Jonathan Beesley4, Kyriaki Michailidou3, John L Hopper5, Carmel Apicella5, Melissa C Southey6, Jennifer Stone7, Marjanka K Schmidt8, Annegien Broeks8, Laura J Van't Veer8, Emiel J Th Rutgers8, Kenneth Muir9, Artitaya Lophatananon10, Sarah Stewart-Brown10, Pornthep Siriwanarangsan11, Peter A Fasching12, Lothar Haeberle13, Arif B Ekici14, Matthias W Beckmann13, Julian Peto15, Isabel Dos-Santos-Silva15, Olivia Fletcher16, Nichola Johnson16, Manjeet K Bolla3, Qin Wang3, Joe Dennis3, Elinor J Sawyer17, Timothy Cheng18, Ian Tomlinson18, Michael J Kerin19, Nicola Miller19, Frederik Marmé20, Harald M Surowy21, Barbara Burwinkel21, Pascal Guénel22, Thérèse Truong22, Florence Menegaux22, Claire Mulot23, Stig E Bojesen24, Børge G Nordestgaard24, Sune F Nielsen25, Henrik Flyger26, Javier Benitez27, M Pilar Zamora28, Jose Ignacio Arias Perez29, Primitiva Menéndez30, Anna González-Neira31, Guillermo Pita31, M Rosario Alonso31, Nuria Alvarez31, Daniel Herrero31, Hoda Anton-Culver32, Hermann Brenner33, Aida Karina Dieffenbach33, Volker Arndt34, Christa Stegmaier35, Alfons Meindl36, Peter Lichtner37, Rita K Schmutzler38, Bertram Müller-Myhsok39, Hiltrud Brauch40, Thomas Brüning41, Yon-Dschun Ko42, GENICA Network, Daniel C Tessier43, Daniel Vincent43, Francois Bacot43, Heli Nevanlinna44, Kristiina Aittomäki45, Carl Blomqvist46, Sofia Khan44, Keitaro Matsuo47, Hidemi Ito48, Hiroji Iwata49, Akiyo Horio49, Natalia V Bogdanova50, Natalia N Antonenkova51, Thilo Dörk52, Annika Lindblom53, Sara Margolin54, Arto Mannermaa55, Vesa Kataja56, Veli-Matti Kosma55, Jaana M Hartikainen55, kConFab Investigators, Australian Ovarian Cancer Study Group, Anna H Wu57, Chiu-Chen Tseng57, David Van Den Berg57, Daniel O Stram57, Patrick Neven58, Els Wauters59, Hans Wildiers60, Diether Lambrechts61, Jenny Chang-Claude62, Anja Rudolph62, Petra Seibold62, Dieter Flesch-Janys63, Paolo Radice64, Paolo Peterlongo65, Siranoush Manoukian66, Bernardo Bonanni67, Fergus J Couch68, Xianshu Wang68, Celine Vachon69, Kristen Purrington70, Graham G Giles71, Roger L Milne71, Catriona Mclean72, Christopher A Haiman57, Brian E Henderson57, Fredrick Schumacher57, Loic Le Marchand73, Jacques Simard74, Mark S Goldberg75, France Labrèche76, Martine Dumont74, Soo Hwang Teo77, Cheng Har Yip78, Norhashimah Hassan77, Eranga Nishanthie Vithana79, Vessela Kristensen80, Wei Zheng81, Sandra Deming-Halverson81, Martha J Shrubsole81, Jirong Long81, Robert Winqvist82, Katri Pylkäs82, Arja Jukkola-Vuorinen83, Saila Kauppila84, Irene L Andrulis85, Julia A Knight86, Gord Glendon87, Sandrine Tchatchou88, Peter Devilee89, Robert A E M Tollenaar90, Caroline Seynaeve91, Christi J Van Asperen92, Montserrat García-Closas93, Jonine Figueroa94, Jolanta Lissowska95, Louise Brinton94, Kamila Czene96, Hatef Darabi96, Mikael Eriksson96, Judith S Brand96, Maartje J Hooning91, Antoinette Hollestelle91, Ans M W Van Den Ouweland97, Agnes Jager91, Jingmei Li98, Jianjun Liu99, Keith Humphreys96, Xiao-Ou Shu81, Wei Lu98, Yu-Tang Gao100, Hui Cai81, Simon S Cross101, Malcolm W R Reed102, William Blot103, Lisa B Signorello103, Qiuyin Cai81, Paul D P Pharoah104, Barbara Perkins105, Mitul Shah105, Fiona M Blows105, Daehee Kang106, Keun-Young Yoo107, Dong-Young Noh108, Mikael Hartman109, Hui Miao110, Kee Seng Chia110, Thomas Choudary Putti111, Ute Hamann112, Craig Luccarini105, Caroline Baynes105, Shahana Ahmed105, Mel Maranian105, Catherine S Healey105, Anna Jakubowska113, Jan Lubinski113, Katarzyna Jaworska-Bieniek113, Katarzyna Durda113, Suleeporn Sangrajrang114, Valerie Gaborieau115, Paul Brennan115, James Mckay115, Susan Slager69, Amanda E Toland116, Drakoulis Yannoukakos117, Chen-Yang Shen118, Chia-Ni Hsiung119, Pei-Ei Wu120, Shian-Ling Ding121, Alan Ashworth122, Michael Jones123, Nick Orr124, Anthony J Swerdlow125, Helen Tsimiklis126, Enes Makalic127, Daniel F Schmidt127, Quang M Bui127, Stephen J Chanock94, David J Hunter128, Rebecca Hein129, Norbert Dahmen130, Lars Beckmann131, Kirsimari Aaltonen44, Taru A Muranen44, Tuomas Heikkinen44, Astrid Irwanto99, Nazneen Rahman123, Clare A Turnbull123, Breast and Ovarian Cancer Susceptibility (BOCS) Study, Quinten Waisfisz132, Hanne E J Meijers-Heijboer132, Muriel A Adank132, Rob B Van Der Luijt133, Per Hall96, Georgia Chenevix-Trench4, Alison Dunning105, Douglas F Easton104, Angela Cox134
Author Affiliations
1: Department of Oncology, University of Sheffield Medical School, Sheffield S10 2RX, UK Department of Neurosurgery, Chang Gung Memorial Hospital, Taoyuan County 333, Taiwan.
2: Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108-1266, USA.
3: Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care.
4: Department of Genetics.
5: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health.
6: Department of Pathology.
7: Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health.
8: Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam 1066 CX, the Netherlands.
9: Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK Institute of Population Health, University of Manchester, Manchester M13 9QQ, UK.
10: Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK.
11: Ministry of Public Health, Nonthaburi 11000, Thailand.
12: University Breast Center Franconia, Department of Gynecology and Obstetrics David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California, Los Angeles, CA 90095, USA.
13: University Breast Center Franconia, Department of Gynecology and Obstetrics.
14: Institute of Human Genetics, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen D-91054, Germany.
15: Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
16: Breakthrough Breast Cancer Research Centre.
17: Division of Cancer Studies, Kings College London, Guy's Hospital, London SE1 9RT, UK.
18: Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7BN, UK.
19: School of Medicine, National University of Ireland, Galway, Ireland.
20: Department of Obstetrics and Gynecology National Center for Tumor Diseases, University of Heidelberg, Heidelberg 69117, Germany.
21: Department of Obstetrics and Gynecology Molecular Epidemiology Group.
22: Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif 94807, France University Paris-Sud, UMRS 1018, Villejuif 94807, France.
23: Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris 75015, France.
24: Copenhagen General Population Study, Herlev Hospital, 2730 Herlev, Copenhagen, Denmark Department of Clinical Biochemistry Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
25: Copenhagen General Population Study, Herlev Hospital, 2730 Herlev, Copenhagen, Denmark Department of Clinical Biochemistry.
26: Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen 2100, Denmark.
27: Human Genetics Group, Human Cancer Genetics Program Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia 28029, Spain.
28: Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid 28046, Spain.
29: Servicio de Cirugía General y Especialidades.
30: Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo 33012, Spain.
31: Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid E-28029, Spain.
32: Department of Epidemiology, University of California Irvine, Irvine, CA 92697, USA.
33: Division of Clinical Epidemiology and Aging Research German Cancer Consortium (DKTK), Heidelberg, Germany.
34: Division of Clinical Epidemiology and Aging Research.
35: Saarland Cancer Registry, Saarbrücken 66024, Germany.
36: Division of Gynaecology and Obstetrics.
37: Insitute of Human Genetics, Technische Universität München, Munich D-80333, Germany.
38: Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, 50932 Cologne, Germany.
39: Max Planck Institute of Psychiatry, Munich 80804, Germany.
40: Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany University of Tübingen, Tübingen 72074, Germany German Cancer Consortium (DKTK).
41: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bochum D-44789, Germany.
42: Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn 53113, Germany.
43: Centre D'innovation Génome Québec et Université McGill, Montréal, QC, Canada H3A 0G1.
44: Department of Obstetrics and Gynecology Helsinki University Central Hospital, Helsinki 00029, Finland.
45: Department of Clinical Genetics Helsinki University Central Hospital, Helsinki 00029, Finland.
46: Department of Oncology, University of Helsinki Helsinki University Central Hospital, Helsinki 00029, Finland.
47: Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka 812-8582, Japan.
48: Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.
49: Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
50: Department of Obstetrics and Gynaecology Department of Radiation Oncology, Hannover Medical School, Hannover 30625, Germany.
51: N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk 223040, Belarus.
52: Department of Obstetrics and Gynaecology.
53: Department of Molecular Medicine and Surgery.
54: Department of Oncology-Pathology.
55: School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine and Cancer Center of Eastern Finland Imaging Center, Department of Clinical Pathology.
56: School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio 70210, Finland Cancer Center, Kuopio University Hospital, Kuopio 70029, Finland.
57: Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
58: University Hospital Gashuisberg, Leuven 3000, Belgium.
59: Vesalius Research Center (VRC), VIB, Leuven 3000, Belgium Department of Oncology.
60: Department of General Medical Oncology, University Hospitals Leuven, Leuven 3000, Belgium.
61: Vesalius Research Center (VRC), VIB, Leuven 3000, Belgium Laboratory for Translational Genetics, Department of Oncology.
62: Division of Cancer Epidemiology.
63: Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg D-20246, Germany.
64: Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine.
65: IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan 20139, Italy.
66: Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan 20133, Italy.
67: Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan 20141, Italy.
68: Department of Laboratory Medicine and Pathology.
69: Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
70: Karmanos Cancer Center, Detroit, MI 48201, USA.
71: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC 3004, Australia.
72: Anatomical Pathology, The Alfred Hospital, Melbourne, VIC 3004, Australia.
73: Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
74: Centre Hospitalier Universitaire de Québec Research Centre and Laval University, Quebec City, QC, Canada G1V 4G2.
75: Department of Medicine, McGill University, Montreal, QC, Canada H3A 0G4 Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada H3A 1A1.
76: Départements de Santé Environnementale et Santé au Travail et de Médecine Sociale et Préventive, École de Santé Publique, Université de Montréal, Montreal, QC, Canada H3T 1J4.
77: Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur 50603, Malaysia.
78: Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur 50603, Malaysia.
79: Singapore Eye Research Institute, National University of Singapore, Singapore 119077, Singapore.
80: Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo 0372, Norway Faculty of Medicine (Faculty Division Ahus), University of Oslo (UiO), Oslo 0316, Norway.
81: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
82: Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, Northern Finland Laboratory Centre NordLab.
83: Department of Oncology.
84: Department of Pathology, Oulu University Hospital, University of Oulu, Oulu 90570, Finland.
85: Ontario Cancer Genetics Network Department of Molecular Genetics.
86: Prosserman Centre for Health Research Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada M5S 2J7.
87: Ontario Cancer Genetics Network.
88: Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5.
89: Department of Human Genetics & Department of Pathology.
90: Department of Surgical Oncology.
91: Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Cancer Institute Rotterdam 3075 EA, The Netherlands.
92: Department of Clinical Genetics, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
93: Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research Division of Genetics and Epidemiology.
94: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
95: Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw 02-781, Poland.
96: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden.
97: Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3075 EA, The Netherlands.
98: Shanghai Center for Disease Control and Prevention, Shanghai 200336, China.
99: Human Genetics Division, Genome Institute of Singapore, Singapore 138672, Singapore.
100: Department of Epidemiology, Shanghai Cancer Institute, Shanghai 220025, China.
101: Department of Neuroscience, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
102: Department of Oncology, University of Sheffield Medical School, Sheffield S10 2RX, UK.
103: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA International Epidemiology Institute, Rockville, MD 20850, USA.
104: Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
105: Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
106: Department of Preventive Medicine Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 151-742, Korea.
107: Seoul National University College of Medicine, Seoul 110-799, Korea.
108: Department of Surgery.
109: Saw Swee Hock School of Public Health Department of Surgery, Yong Loo Lin School of Medicine National University Health System, Singapore 119228, Singapore.
110: Saw Swee Hock School of Public Health National University Health System, Singapore 119228, Singapore.
111: Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
112: Molecular Genetics of Breast Cancer.
113: Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland.
114: National Cancer Institute, Bangkok 10400, Thailand.
115: International Agency for Research on Cancer, Lyon 69372, France.
116: Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
117: Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, Athens 153 10, Greece.
118: Institute of Biomedical Sciences College of Public Health, China Medical University, Taichung 40402, Taiwan.
119: Institute of Biomedical Sciences.
120: Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
121: Department of Nursing, Kang-Ning Junior College of Medical Care and Management, Taipei 11529, Taiwan.
122: Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research.
123: Division of Genetics and Epidemiology.
124: Breakthrough Breast Cancer Research Centre and Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK.
125: Division of Genetics and Epidemiology Division of Breast Cancer Research.
126: Genetic Epidemiology Laboratory, Department of Pathology.
127: Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Melbourne, VIC 3010, Australia.
128: Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
129: Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Cologne 50923, Germany.
130: Department of Psychiatry, University of Mainz, Mainz 55122, Germany.
131: Institute for Quality and Efficiency in Health Care (IQWiG), Cologne 50670, Germany.
132: Department of Clinical Genetics, Section Oncogenetics, VU University Medical Center, Amsterdam 1081 HZ, The Netherlands and.
133: Department of Medical Genetics, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.
134: Department of Oncology, University of Sheffield Medical School, Sheffield S10 2RX, UK a.cox@sheffield.ac.uk.
Articles by these authors ⇆
Genetic studies of body mass index yield new insights for obesity biology. Nature (2015) 8.27
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet (2015) 3.02
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res (2006) 2.79
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer (2008) 2.14
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol (2013) 2.11
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature (2014) 1.88
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. J Clin Oncol (2008) 1.81
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res (2011) 1.79
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res (2007) 1.61
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiol (2015) 1.56
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One (2010) 1.54
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol (2010) 1.52
Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res (2010) 1.51
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med (2015) 1.50
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet (2015) 1.47
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer (2013) 1.47
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet (2009) 1.42
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell (2010) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol (2012) 1.39
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev (2007) 1.34
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res (2008) 1.27
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26
Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet (2005) 1.25
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A (2013) 1.22
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2014) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol (2013) 1.20
Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One (2011) 1.20
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun (2014) 1.19